logo

Alexion Pharmaceuticals Inc. (ALXN)



Trade ALXN now with
  Date
  Headline
12/26/2017 6:31:28 AM Alexion : Soliris Gets Marketing Authorization In Japan For Treatment Of Patients With Generalized Myasthenia Gravis
12/11/2017 10:02:09 AM Alexion Announces Presentation Of Comprehensive Dose-ranging Data From Two Phase 1b/2 Studies Of ALXN1210
12/7/2017 6:31:21 AM Alexion And Halozyme Enter License Deal For ENHANZE Technology
11/8/2017 4:06:11 PM Alexion Appoints Francois Nader To Its Board Of Directors
11/6/2017 6:30:40 AM Alexion Receives New Japanese Patent For Soliris, Extending Patent Protection Into 2027
11/1/2017 9:26:05 AM Alexion To Present New Phase 1/2 Study Data For ALXN1210
10/27/2017 11:13:27 AM RBC Capital Markets Is Raising Alexion Pharmaceuticals Inc. (ALXN) 4Q17 Estimate To 0.37 From 0.07
10/27/2017 11:13:11 AM RBC Capital Markets Is Lowering Alexion Pharmaceuticals Inc. (ALXN) 4Q17 Rev. Estimate To 879.0 M From 882.0 M
10/27/2017 11:11:07 AM RBC Capital Markets Is Cutting Alexion Pharmaceuticals Inc. (ALXN) 2019 Estimate To 4.67 From 4.91
10/27/2017 11:10:56 AM RBC Capital Markets Is Cutting Alexion Pharmaceuticals Inc. (ALXN) 2018 Estimate To 3.03 From 3.32
10/27/2017 11:10:40 AM RBC Capital Markets Is Raising Alexion Pharmaceuticals Inc. (ALXN) 2017 Estimate To 2.19 From 1.87
10/27/2017 11:10:07 AM RBC Capital Markets Is Lowering Alexion Pharmaceuticals Inc. (ALXN) 2019 Rev. Estimate To 4697.0 M From 4829.0 M
10/27/2017 11:09:52 AM RBC Capital Markets Is Lowering Alexion Pharmaceuticals Inc. (ALXN) 2018 Rev. Estimate To 3907.0 M From 3999.0 M